Origen Therapeutics’ goal is to develop next generation antibody therapeutics using its proprietary transgenic animal technology to deliver products via chicken’s eggs.  The company is a leader in developing technology for producing fully human sequence polyclonal antibodies derived from the immune system of chickens.

Vision.
Origen’s vision is to become the leading developer of polyclonal antibody therapeutics, a class of immunotherapeutic which shows promise of greatly enhanced efficacy in treating a wide range of diseases including infectious disease, cancer and autoimmune disease.

Mission.
Origen’s mission is to apply its proprietary avian transgenesis technology to the development of a platform for the discovery, development and commercialization of  fully human sequence polyclonal antibodies.  These antibody therapeutics are expected to show the enhanced target destruction found in natural immune responses which are polyclonal in nature.

Origen Therapeutics is a privately held company, founded in 1997. The company is headquartered in Emeryville, California where the company has established laboratories.